Trump, Xi, and a Defining Moment for the World 
David Lapp on the Case Against Forcing Residential Consumers to Pay for Skyrocketing Data Center Costs 
Elizabeth Burch on the Dark Side of the Tort Bar The deal value represented a 73 per cent jump from the same period a year earlier, and accounted for nearly half of the total US$135.7 billion worth of agreements signed throughout 2025, the National Medical Products Administration (NMPA) said in a statement on Saturday.
The drug regulator did not reveal the number of transactions.
Advertisement
Outlicensing agreements typically involve a company granting another firm the exclusive rights to further develop, manufacture and commercialise a drug once it has entered human clinical trials, in return for upfront payments, milestone fees and royalties on future sales.
“Chinese biotech firms have shown substantial technological advancements over the past few years and some of their innovative research has piqued the interest of international pharmaceutical big names,” said Meng Tianying, a senior executive at Shanghai-based consultancy Domo Medical. “It has become a new bright spot of the Chinese economy in line with the government’s efforts to encourage innovation.”
Advertisement
Innovative drugs – novel medicines targeting unmet medical needs, including new chemical entities and advanced biologics – were expected to grow at an annualised pace of 20 per cent between 2026 and 2030 in mainland China, before slowing to 8.8 per cent from 2030 to 2040, according to Chen Chen, head of China healthcare research at UBS.
Don't Miss:
-
Vance and Rubio emerge as early contenders to inherit Trump’s Republican Party
-
India raises diesel, petrol prices for third time in 8 days, amid tense US-Iran ceasefire
-
Is China building the world’s largest naval support ship?
-
Three Mexican Meth Cooks Arrested at Drug Lab in Nigeria
-
New Zealand to invest almost US$1 billion in drones, ships to protect maritime security